APO Research
Talk to an analyst

APO RESEARCH · REPORT

Paroxetine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Paroxetine Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchParoxetine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Paroxetine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Paroxetine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Paroxetine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Paroxetine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Paroxetine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Paroxetine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Paroxetine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Paroxetine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Paroxetine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Paroxetine market include Teva, Sun Pharmaceutical, Mylan, Aurobindo, Sebela Pharmaceuticals, Neurocon Inc, Lupin, Lifegenix and Lannett Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Paroxetine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Paroxetine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Paroxetine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Paroxetine market size, projected growth trends, production technologies, key applications, and end-use industries.

Paroxetine Segment by Company

Teva

Sun Pharmaceutical

Mylan

Aurobindo

Sebela Pharmaceuticals

Neurocon Inc

Lupin

Lifegenix

Lannett Company

Jubilant Pharma

Apotex

Paroxetine Segment by Type

Paroxetine Hydrochloride Drug

Paroxetine Mesylate Drug

Paroxetine Segment by Application

Depression

Social anxiety disorder

Panic disorder

Others

Paroxetine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Paroxetine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Paroxetine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Paroxetine significant trends, drivers, influence factors in global and regions.

6. To analyze Paroxetine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Paroxetine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Paroxetine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Paroxetine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Paroxetine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Paroxetine industry.

Chapter 3: Detailed analysis of Paroxetine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Paroxetine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Paroxetine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Paroxetine Industry Trends Table 2. Paroxetine Industry Drivers Table 3. Paroxetine Industry Opportunities and Challenges Table 4. Paroxetine Industry Restraints Table 5. Global Paroxetine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Paroxetine Revenue Share by Company (2021-2026) Table 7. Global Paroxetine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Paroxetine Sales Volume Share by Company (2021-2026) Table 9. Global Paroxetine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Paroxetine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Paroxetine Key Company Manufacturing Base & Headquarters Table 12. Global Paroxetine Company, Product Type & Application Table 13. Global Paroxetine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Paroxetine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Paroxetine Hydrochloride Drug Table 18. Significant Companies of Paroxetine Mesylate Drug Table 19. Global Paroxetine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Paroxetine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Paroxetine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Paroxetine Sales Volume Share by Type (2021-2026) Table 23. Global Paroxetine Sales Volume Share by Type (2027-2032) Table 24. Global Paroxetine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Paroxetine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Paroxetine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Paroxetine Sales Value Share by Type (2021-2026) Table 28. Global Paroxetine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Depression Table 30. Significant Companies of Social anxiety disorder Table 31. Significant Companies of Panic disorder Table 32. Significant Companies of Others Table 33. Global Paroxetine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Paroxetine Sales Volume by Application (2021-2026) & (k units) Table 35. Global Paroxetine Sales Volume by Application (2027-2032) & (k units) Table 36. Global Paroxetine Sales Volume Share by Application (2021-2026) Table 37. Global Paroxetine Sales Volume Share by Application (2027-2032) Table 38. Global Paroxetine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Paroxetine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Paroxetine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Paroxetine Sales Value Share by Application (2021-2026) Table 42. Global Paroxetine Sales Value Share by Application (2027-2032) Table 43. Global Paroxetine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Paroxetine Sales by Region (2021-2026) & (k units) Table 45. Global Paroxetine Sales Market Share by Region (2021-2026) Table 46. Global Paroxetine Sales by Region (2027-2032) & (k units) Table 47. Global Paroxetine Sales Market Share by Region (2027-2032) Table 48. Global Paroxetine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Paroxetine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Paroxetine Sales Value Share by Region (2021-2026) Table 51. Global Paroxetine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Paroxetine Sales Value Share by Region (2027-2032) Table 53. Global Paroxetine Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Paroxetine Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Paroxetine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Paroxetine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Paroxetine Sales by Country (2021-2026) & (k units) Table 58. Global Paroxetine Sales Market Share by Country (2021-2026) Table 59. Global Paroxetine Sales by Country (2027-2032) & (k units) Table 60. Global Paroxetine Sales Market Share by Country (2027-2032) Table 61. Global Paroxetine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Paroxetine Sales Value Market Share by Country (2021-2026) Table 63. Global Paroxetine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Paroxetine Sales Value Market Share by Country (2027-2032) Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Teva Paroxetine Product Portfolio Table 69. Teva Recent Development Table 70. Sun Pharmaceutical Company Information Table 71. Sun Pharmaceutical Business Overview Table 72. Sun Pharmaceutical Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Sun Pharmaceutical Paroxetine Product Portfolio Table 74. Sun Pharmaceutical Recent Development Table 75. Mylan Company Information Table 76. Mylan Business Overview Table 77. Mylan Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Mylan Paroxetine Product Portfolio Table 79. Mylan Recent Development Table 80. Aurobindo Company Information Table 81. Aurobindo Business Overview Table 82. Aurobindo Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Aurobindo Paroxetine Product Portfolio Table 84. Aurobindo Recent Development Table 85. Sebela Pharmaceuticals Company Information Table 86. Sebela Pharmaceuticals Business Overview Table 87. Sebela Pharmaceuticals Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Sebela Pharmaceuticals Paroxetine Product Portfolio Table 89. Sebela Pharmaceuticals Recent Development Table 90. Neurocon Inc Company Information Table 91. Neurocon Inc Business Overview Table 92. Neurocon Inc Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Neurocon Inc Paroxetine Product Portfolio Table 94. Neurocon Inc Recent Development Table 95. Lupin Company Information Table 96. Lupin Business Overview Table 97. Lupin Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Lupin Paroxetine Product Portfolio Table 99. Lupin Recent Development Table 100. Lifegenix Company Information Table 101. Lifegenix Business Overview Table 102. Lifegenix Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Lifegenix Paroxetine Product Portfolio Table 104. Lifegenix Recent Development Table 105. Lannett Company Company Information Table 106. Lannett Company Business Overview Table 107. Lannett Company Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Lannett Company Paroxetine Product Portfolio Table 109. Lannett Company Recent Development Table 110. Jubilant Pharma Company Information Table 111. Jubilant Pharma Business Overview Table 112. Jubilant Pharma Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Jubilant Pharma Paroxetine Product Portfolio Table 114. Jubilant Pharma Recent Development Table 115. Apotex Company Information Table 116. Apotex Business Overview Table 117. Apotex Paroxetine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Apotex Paroxetine Product Portfolio Table 119. Apotex Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Paroxetine Distributors List Table 123. Paroxetine Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Paroxetine Product Image Figure 2. Global Paroxetine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Paroxetine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Paroxetine Sales (2021-2032) & (k units) Figure 5. Global Paroxetine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Paroxetine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Paroxetine Hydrochloride Drug Image Figure 10. Paroxetine Mesylate Drug Image Figure 11. Global Paroxetine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Paroxetine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Paroxetine Sales Volume Share by Type (2021-2032) Figure 14. Global Paroxetine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Paroxetine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Paroxetine Sales Value Share by Type (2021-2032) Figure 17. Depression Image Figure 18. Social anxiety disorder Image Figure 19. Panic disorder Image Figure 20. Others Image Figure 21. Global Paroxetine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Paroxetine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Paroxetine Sales Volume Share by Application (2021-2032) Figure 24. Global Paroxetine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Paroxetine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Paroxetine Sales Value Share by Application (2021-2032) Figure 27. Global Paroxetine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Paroxetine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Paroxetine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Paroxetine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Paroxetine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Paroxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Paroxetine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Paroxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Paroxetine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Paroxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Paroxetine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Paroxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Paroxetine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Paroxetine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Paroxetine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Paroxetine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Paroxetine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Paroxetine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Paroxetine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Paroxetine Hydrochloride Drug
  • Paroxetine Mesylate Drug
Applications
  • Depression
  • Social anxiety disorder
  • Panic disorder
  • Others
Companies covered
  • Teva
  • Sun Pharmaceutical
  • Mylan
  • Aurobindo
  • Sebela Pharmaceuticals
  • Neurocon Inc
  • Lupin
  • Lifegenix
  • Lannett Company
  • Jubilant Pharma
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Paroxetine Sales Value (2021-2032)
  4. 1.2.2 Global Paroxetine Sales Volume (2021-2032)
  5. 1.2.3 Global Paroxetine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Paroxetine Market Dynamics
  1. 2.1 Paroxetine Industry Trends
  2. 2.2 Paroxetine Industry Drivers
  3. 2.3 Paroxetine Industry Opportunities and Challenges
  4. 2.4 Paroxetine Industry Restraints
3 Paroxetine Market by Company
  1. 3.1 Global Paroxetine Company Revenue Ranking in 2025
  2. 3.2 Global Paroxetine Revenue by Company (2021-2026)
  3. 3.3 Global Paroxetine Sales Volume by Company (2021-2026)
  4. 3.4 Global Paroxetine Average Price by Company (2021-2026)
  5. 3.5 Global Paroxetine Company Ranking (2024-2026)
  6. 3.6 Global Paroxetine Company Manufacturing Base and Headquarters
  7. 3.7 Global Paroxetine Company Product Type and Application
  8. 3.8 Global Paroxetine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Paroxetine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Paroxetine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Paroxetine Market by Type
  1. 4.1 Paroxetine Type Introduction
  2. 4.1.1 Paroxetine Hydrochloride Drug
  3. 4.1.2 Paroxetine Mesylate Drug
  4. 4.2 Global Paroxetine Sales Volume by Type
  5. 4.2.1 Global Paroxetine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Paroxetine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Paroxetine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Paroxetine Sales Value by Type
  9. 4.3.1 Global Paroxetine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Paroxetine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Paroxetine Sales Value Share by Type (2021-2032)
5 Paroxetine Market by Application
  1. 5.1 Paroxetine Application Introduction
  2. 5.1.1 Depression
  3. 5.1.2 Social anxiety disorder
  4. 5.1.3 Panic disorder
  5. 5.1.4 Others
  6. 5.2 Global Paroxetine Sales Volume by Application
  7. 5.2.1 Global Paroxetine Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Paroxetine Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Paroxetine Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Paroxetine Sales Value by Application
  11. 5.3.1 Global Paroxetine Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Paroxetine Sales Value by Application (2021-2032)
  13. 5.3.3 Global Paroxetine Sales Value Share by Application (2021-2032)
6 Paroxetine Regional Sales and Value Analysis
  1. 6.1 Global Paroxetine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Paroxetine Sales by Region (2021-2032)
  3. 6.2.1 Global Paroxetine Sales by Region: 2021-2026
  4. 6.2.2 Global Paroxetine Sales by Region (2027-2032)
  5. 6.3 Global Paroxetine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Paroxetine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Paroxetine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Paroxetine Sales Value by Region (2027-2032)
  9. 6.5 Global Paroxetine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Paroxetine Sales Value (2021-2032)
  12. 6.6.2 North America Paroxetine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Paroxetine Sales Value (2021-2032)
  15. 6.7.2 Europe Paroxetine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Paroxetine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Paroxetine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Paroxetine Sales Value (2021-2032)
  21. 6.9.2 South America Paroxetine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Paroxetine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Paroxetine Sales Value Share by Country, 2025 VS 2032
7 Paroxetine Country-level Sales and Value Analysis
  1. 7.1 Global Paroxetine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Paroxetine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Paroxetine Sales by Country (2021-2032)
  4. 7.3.1 Global Paroxetine Sales by Country (2021-2026)
  5. 7.3.2 Global Paroxetine Sales by Country (2027-2032)
  6. 7.4 Global Paroxetine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Paroxetine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Paroxetine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Paroxetine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Paroxetine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Paroxetine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Paroxetine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Paroxetine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Paroxetine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Paroxetine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Paroxetine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Paroxetine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Paroxetine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Paroxetine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Paroxetine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Paroxetine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Paroxetine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Paroxetine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Paroxetine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Paroxetine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Paroxetine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Paroxetine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Paroxetine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Paroxetine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Paroxetine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Paroxetine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Paroxetine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Paroxetine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Paroxetine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Paroxetine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Paroxetine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Paroxetine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Paroxetine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Paroxetine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Paroxetine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Paroxetine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Paroxetine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Paroxetine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Paroxetine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Paroxetine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Paroxetine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Paroxetine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Paroxetine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Paroxetine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Paroxetine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Paroxetine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Paroxetine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Paroxetine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Paroxetine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Paroxetine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Paroxetine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Paroxetine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Paroxetine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Paroxetine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Paroxetine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Paroxetine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Paroxetine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Paroxetine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Paroxetine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Paroxetine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Paroxetine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Paroxetine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Paroxetine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Paroxetine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Paroxetine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Paroxetine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Paroxetine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Paroxetine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Paroxetine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Paroxetine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Paroxetine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Paroxetine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Paroxetine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Paroxetine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Paroxetine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Paroxetine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Paroxetine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Paroxetine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Paroxetine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Paroxetine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Paroxetine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Paroxetine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Paroxetine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Paroxetine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Paroxetine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Paroxetine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Paroxetine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Paroxetine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Paroxetine Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sun Pharmaceutical
  8. 8.2.1 Sun Pharmaceutical Company Information
  9. 8.2.2 Sun Pharmaceutical Business Overview
  10. 8.2.3 Sun Pharmaceutical Paroxetine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Paroxetine Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Paroxetine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Paroxetine Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Aurobindo
  20. 8.4.1 Aurobindo Company Information
  21. 8.4.2 Aurobindo Business Overview
  22. 8.4.3 Aurobindo Paroxetine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Aurobindo Paroxetine Product Portfolio
  24. 8.4.5 Aurobindo Recent Developments
  25. 8.5 Sebela Pharmaceuticals
  26. 8.5.1 Sebela Pharmaceuticals Company Information
  27. 8.5.2 Sebela Pharmaceuticals Business Overview
  28. 8.5.3 Sebela Pharmaceuticals Paroxetine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sebela Pharmaceuticals Paroxetine Product Portfolio
  30. 8.5.5 Sebela Pharmaceuticals Recent Developments
  31. 8.6 Neurocon Inc
  32. 8.6.1 Neurocon Inc Company Information
  33. 8.6.2 Neurocon Inc Business Overview
  34. 8.6.3 Neurocon Inc Paroxetine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Neurocon Inc Paroxetine Product Portfolio
  36. 8.6.5 Neurocon Inc Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin Paroxetine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lupin Paroxetine Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Lifegenix
  44. 8.8.1 Lifegenix Company Information
  45. 8.8.2 Lifegenix Business Overview
  46. 8.8.3 Lifegenix Paroxetine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lifegenix Paroxetine Product Portfolio
  48. 8.8.5 Lifegenix Recent Developments
  49. 8.9 Lannett Company
  50. 8.9.1 Lannett Company Company Information
  51. 8.9.2 Lannett Company Business Overview
  52. 8.9.3 Lannett Company Paroxetine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Lannett Company Paroxetine Product Portfolio
  54. 8.9.5 Lannett Company Recent Developments
  55. 8.10 Jubilant Pharma
  56. 8.10.1 Jubilant Pharma Company Information
  57. 8.10.2 Jubilant Pharma Business Overview
  58. 8.10.3 Jubilant Pharma Paroxetine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jubilant Pharma Paroxetine Product Portfolio
  60. 8.10.5 Jubilant Pharma Recent Developments
  61. 8.11 Apotex
  62. 8.11.1 Apotex Company Information
  63. 8.11.2 Apotex Business Overview
  64. 8.11.3 Apotex Paroxetine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Apotex Paroxetine Product Portfolio
  66. 8.11.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Paroxetine Value Chain Analysis
  2. 9.1.1 Paroxetine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Paroxetine Sales Mode & Process
  6. 9.2 Paroxetine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Paroxetine Distributors
  9. 9.2.3 Paroxetine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst